Tarsus Pharmaceuticals (TARS) EBITDA (2019 - 2026)

Tarsus Pharmaceuticals' EBITDA history runs 8 years deep, the most recent figure standing at -$7.6 million for Q1 2026.

• In Q1 2026, EBITDA rose 69.68% year-over-year to -$7.6 million; the TTM figure through Mar 2026 stood at -$48.6 million (up 53.58% YoY), while the FY2025 annual figure was -$66.2 million, up 42.61% from the prior year.
• EBITDA was -$7.6 million for Q1 2026 at Tarsus Pharmaceuticals, up from -$8.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$5.7 million in Q2 2022 to a low of -$41.9 million in Q4 2023.
• Historically, EBITDA has averaged -$22.8 million across 5 years, with a median of -$22.9 million in 2024.
• The sharpest annual moves came in 2023 and 2026: EBITDA sank 446.35% in 2023, then jumped 69.68% in 2026.
• A 5-year view of EBITDA shows it stood at -$13.7 million in 2022, then slumped by 206.64% to -$41.9 million in 2023, then soared by 44.43% to -$23.3 million in 2024, then jumped by 64.43% to -$8.3 million in 2025, then gained by 7.67% to -$7.6 million in 2026.
• The last three EBITDA figures came in at -$7.6 million (Q1 2026), -$8.3 million (Q4 2025), and -$12.3 million (Q3 2025), per Business Quant data.